Biomedicines (Aug 2022)

Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients

  • Tabatha Petrillo,
  • Elisa Semprini,
  • Veronica Tomatis,
  • Melania Arnesano,
  • Fedora Ambrosetti,
  • Christian Battipaglia,
  • Alessandra Sponzilli,
  • Francesco Ricciardiello,
  • Andrea R. Genazzani,
  • Alessandro D. Genazzani

DOI
https://doi.org/10.3390/biomedicines10081924
Journal volume & issue
Vol. 10, no. 8
p. 1924

Abstract

Read online

Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient’s BMI, the presence or absence of familiar predisposition to diabetes, and the patient’s desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances.

Keywords